{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T01:41:13Z","timestamp":1784943673930,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Induction chemotherapy (IC) for patients with locally advanced stage Head and Neck Squamous Cell Carcinomas (HNSCC) before radio-chemotherapy (RCT) or surgery remains a potential treatment option. This study analyzed how the response to IC correlates with survival outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a retrospective single-center study at a tertiary cancer center. Tumors were categorized by anatomical site and response to IC (non-responders vs. responders). Data were analyzed using Kaplan-Meier survival curves and Cox regression analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 48 patients received IC. Of these, 33 patients were radiologically evaluable for response. The majority of evaluable patients received either TPF (Docetaxel, Cisplatin, 5-Fluorouracil) (58%) or TP (Docetaxel, Cisplatin) (24%) as their IC regimen. Tumor reduction of 30% or more was observed in 23 patients (69.7%), the tumor control rate was 97%. The 2-year event-free survival (EFS) in the IC evaluable population was 53.1%, overall survival (OS) was 63.6%, and recurrence-free survival (RFS) was 62.5%. Patients with laryngeal or hypopharyngeal tumors that did not respond to IC had a significantly poorer prognosis. This effect was not statistically significant in tumors of the oral cavity or oropharynx, where it was only observed as a trend.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>IC is highly effective in treating locally advanced stage HNSCC. The response to IC is prognostic for survival, particularly in cancers of the larynx and hypopharynx.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00432-024-06044-2","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T04:00:22Z","timestamp":1733284822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Response to induction chemotherapy as a prognostic indicator in locally advanced head and neck squamous cell carcinoma"],"prefix":"10.1007","volume":"151","author":[{"given":"Francesca","family":"Huwyler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Giger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Bill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9721-3314","authenticated-orcid":false,"given":"Simon","family":"Haefliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"6044_CR1","unstructured":"Cancer Today. (n.d.). Retrieved September 11 (2024) from https:\/\/gco.iarc.who.int\/today\/en"},{"issue":"25","key":"6044_CR2","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1200\/JCO.2013.54.6309","volume":"32","author":"EEW Cohen","year":"2014","unstructured":"Cohen EEW, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Vokes EE (2014) Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncology: Official J Am Soc Clin Oncol 32(25):2735\u20132743. https:\/\/doi.org\/10.1200\/JCO.2013.54.6309","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"6044_CR3","doi-asserted-by":"publisher","unstructured":"Drawing Survival Curves using ggplot2 [R package survminer version 0.4.9]. (2021) https:\/\/doi.org\/10.32614\/CRAN.PACKAGE.SURVMINER","DOI":"10.32614\/CRAN.PACKAGE.SURVMINER"},{"issue":"31","key":"6044_CR4","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1200\/JCO.2017.76.2591","volume":"36","author":"L Geoffrois","year":"2018","unstructured":"Geoffrois L, Martin L, De Raucourt D, Sun XS, Tao Y, Maingon P, Buffet J, Pointreau Y, Sire C, Tuchais C, Babin E, Coutte A, Rolland F, Kaminsky M-C, Alfonsi M, Lapeyre M, Saliou M, Lafond C, Jadaud E, Bourhis J (2018) Induction chemotherapy followed by Cetuximab Radiotherapy is not Superior to Concurrent Chemoradiotherapy for Head and Neck carcinomas: results of the GORTEC 2007-02 phase III Randomized Trial. J Clin Oncology: Official J Am Soc Clin Oncol 36(31):3077\u20133083. https:\/\/doi.org\/10.1200\/JCO.2017.76.2591","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"9","key":"6044_CR5","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdx299","volume":"28","author":"MG Ghi","year":"2017","unstructured":"Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codec\u00e0 C, Nol\u00e8 F, Verri E, Orecchia R, Morelli F, Parisi S, Mastromauro C, Mione CA, Rossetto C, Polsinelli M, Koussis H, Loreggian L, Bonetti A, Campostrini F (2017) Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Annals Oncology: Official J Eur Soc Med Oncol 28(9):2206\u20132212. https:\/\/doi.org\/10.1093\/annonc\/mdx299. Gruppo di Studio Tumori della Testa e del Collo) Italian Study Group","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"3","key":"6044_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","volume":"14","author":"R Haddad","year":"2013","unstructured":"Haddad R, O\u2019Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M (2013a) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14(3):257\u2013264. https:\/\/doi.org\/10.1016\/S1470-2045(13)70011-1","journal-title":"Lancet Oncol"},{"issue":"3","key":"6044_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","volume":"14","author":"R Haddad","year":"2013","unstructured":"Haddad R, O\u2019Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M (2013b) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14(3):257\u2013264. https:\/\/doi.org\/10.1016\/S1470-2045(13)70011-1","journal-title":"Lancet Oncol"},{"issue":"1","key":"6044_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/annonc\/mdt461","volume":"25","author":"R Hitt","year":"2014","unstructured":"Hitt R, Grau JJ, L\u00f3pez-Pousa A, Berrocal A, Garc\u00eda-Gir\u00f3n C, Irigoyen A, Sastre J, Mart\u00ednez-Trufero J, Brandariz Castelo JA, Verger E, Cruz-Hern\u00e1ndez JJ, Spanish Head and Neck Cancer Cooperative Group (TTCC) (2014) A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Annals Oncology: Official J Eur Soc Med Oncol 25(1):216\u2013225. https:\/\/doi.org\/10.1093\/annonc\/mdt461","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"key":"6044_CR818","doi-asserted-by":"publisher","unstructured":"Janoray G, Pointreau Y, Garaud P, Chapet S, Alfonsi M, Sire C, Jadaud E, Calais G. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, \u00b1 Docetaxel for Larynx Preservation. J Natl Cancer Inst. 2015 Dec 16;108(4):djv368. https:\/\/doi.org\/10.1093\/jnci\/djv368","DOI":"10.1093\/jnci\/djv368"},{"key":"6044_CR9","doi-asserted-by":"publisher","unstructured":"Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR (2020) Head and neck squamous cell carcinoma. Nat Reviews Disease Primers 6(1). https:\/\/doi.org\/10.1038\/S41572-020-00224-3","DOI":"10.1038\/S41572-020-00224-3"},{"issue":"7","key":"6044_CR10","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1002\/lary.27011","volume":"128","author":"KL Kiong","year":"2018","unstructured":"Kiong KL, de Souza NN, Sultana R, Iyer NG (2018) Meta-analysis of induction chemotherapy as a selection marker for chemoradiation in the head and neck. Laryngoscope 128(7):1594\u20131601. https:\/\/doi.org\/10.1002\/lary.27011","journal-title":"Laryngoscope"},{"issue":"1","key":"6044_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4143\/crt.2020.1329","volume":"54","author":"Y-G Lee","year":"2022","unstructured":"Lee Y-G, Kang EJ, Keam B, Choi J-H, Kim J-S, Park KU, Lee KE, Kim HJ, Lee K-W, Kim MK, Ahn HK, Shin SH, Kim HR, Kim S-B, Yun HJ (2022) Induction chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck squamous cell carcinoma: the Concept of Chemo-Selection (KCSG HN13-01). Cancer Res Treat 54(1):109\u2013117. https:\/\/doi.org\/10.4143\/crt.2020.1329","journal-title":"Cancer Res Treat"},{"issue":"3","key":"6044_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/mco2.55","volume":"2","author":"Y-P Liu","year":"2021","unstructured":"Liu Y-P, Zheng C-C, Huang Y-N, He M-L, Xu WW, Li B (2021) Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm 2(3):315\u2013340. https:\/\/doi.org\/10.1002\/mco2.55","journal-title":"MedComm"},{"issue":"2","key":"6044_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1200\/JCO.2015.61.5906","volume":"34","author":"CT Murphy","year":"2016","unstructured":"Murphy CT, Galloway TJ, Handorf EA, Egleston BL, Wang LS, Mehra R, Flieder DB, Ridge JA (2016) Survival impact of increasing time to treatment initiation for patients with Head and Neck Cancer in the United States. J Clin Oncology: Official J Am Soc Clin Oncol 34(2):169\u2013178. https:\/\/doi.org\/10.1200\/JCO.2015.61.5906","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"6044_CR14","doi-asserted-by":"publisher","unstructured":"Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio R del, Venkatesan C, Romanov V, Haddad I (2007) R. I. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. The New England Journal of Medicine, 357(17), 1705\u20131715. https:\/\/doi.org\/10.1056\/NEJMOA070956","DOI":"10.1056\/NEJMOA070956"},{"key":"6044_CR15","doi-asserted-by":"publisher","unstructured":"Therneau TM (2024) Survival Analysis [R package survival version 3.7-0]. https:\/\/doi.org\/10.32614\/CRAN.PACKAGE.SURVIVAL","DOI":"10.32614\/CRAN.PACKAGE.SURVIVAL"},{"issue":"8","key":"6044_CR16","doi-asserted-by":"publisher","first-page":"9175","DOI":"10.1002\/cam4.5656","volume":"12","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Xu T, Shen C, Qian W, Ying H, He X, Wang Y, Ji Q, Hu C, Zhou X, Lu X (2023) Response to induction chemotherapy predicts survival outcomes in oropharyngeal cancer. Cancer Med 12(8):9175\u20139185. https:\/\/doi.org\/10.1002\/cam4.5656","journal-title":"Cancer Med"},{"key":"6044_CR17","doi-asserted-by":"publisher","first-page":"106918","DOI":"10.1016\/j.oraloncology.2024.106918","volume":"156","author":"X Zhao","year":"2024","unstructured":"Zhao X, Zhou Y, Peng G, Wen L, Hong X, Hu Y, Wu B, Liu X, Zhang Z, Xiao G, JingHuang, Ding Q, Yang C, Xiong X, Ma H, Shi L, Yang J, Wei J, Qin Y, Yang K (2024) Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma. Oral Oncol 156:106918. https:\/\/doi.org\/10.1016\/j.oraloncology.2024.106918","journal-title":"Oral Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-06044-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-06044-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-06044-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T07:16:35Z","timestamp":1738998995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-06044-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["6044"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-06044-2","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"16 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol received approval from the Cantonal Ethics Committee of Bern (Project-ID 2020\u201303074).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The ethics committee approved the reuse of clinical data from 2005 to 2013 without requiring additional patient consent. From 2013 onwards, all patients in the study provided general consent for the further use of their clinical data for research purposes at Inselspital, University Hospital Bern.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}